Similar Articles |
|
Chemistry World August 27, 2015 Phillip Broadwith |
Job cuts at Lundbeck and DSM Specialist brain disease drugmaker Lundbeck and materials and life sciences firm DSM are both cutting staff in major restructuring efforts to cut costs and improve profitability. |
Chemistry World September 3, 2013 Patrick Walter |
Lundbeck appeals European antitrust fine Lundbeck is appealing against a euro 93.8 million fine, handed down by the European commission, for its part in blocking market entry of a generic antidepressant. |
Chemistry World March 5, 2013 Andrew Turley |
Alcohol dependence pill approved in EU Danish drug maker Lundbeck has been granted European marketing approval for Selincro (nalmefene) tablets to treat alcohol dependence. |
Chemistry World June 17, 2012 Andrew Turley |
Lundbeck to lose 600 jobs The Danish company says it must cut jobs 'to mitigate increased pressure from healthcare reforms, generic competition and uncertainty regarding pricing and reimbursement in Europe'. |
Bio-IT World August 2005 Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. |
Bio-IT World August 13, 2002 Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Pharmaceutical Executive October 1, 2012 William Looney |
Bidding for the Stars and Stripes As the blockbuster sales model fades, the rush is on for a new formula for growth. "Good" growth: niched, balanced, and sustainable; with high margins from protected pricing; more patient-friendly than patent-centric; and where revenues draw from a deep reservoir of unmet medical need. |